Baxter's fiscal second quarter landed as the moment a balance-sheet-and-portfolio overhaul quietly became an operating story. Worldwide sales from continuing operations rose 5% to $2.96 billion (5% on an organic basis), every operating segment and division grew in both the United States and internationally, U.S. GAAP diluted earnings per share from continuing operations came in at $0.26 versus a year-ago $0.24, and adjusted diluted earnings per share from continuing operations of $0.56 came in 5% lower than the prior year - a modest miss, not a failure, cushioned by an $0.11-per-share benefit from an IEEPA tariff refund that was not in the company's prior guidance. Free cash flow from continuing operations was $181 million for the quarter and $257 million for the first half, the second half of a turn that took operating cash flow from $118 million in H1 2025 to $510 million in H1 2026. Management raised the full-year outlook: reported sales growth from continuing operations of 3% to 4% (up from flat to 1%), organic sales growth of 2% to 3% (up from approximately flat), and adjusted diluted earnings per share from continuing operations of $1.95 to $2.15 (up from $1.85 to $2.05).
The quarter's question is whether the print is durable or borrowed. The medical-products-and-therapies segment's operating margin compressed 350 basis points year over year (from 22.8% to 19.3%) as higher-cost inventory from the end of 2025 rolled through cost of sales and a year-ago reclassification of certain functional costs out of selling, general and administrative inflated the comparison - that is, the GAAP margin print is mostly a one-quarter comp, not a structural deterioration. Beneath the comp distortion, the medical-products-and-therapies segment grew 7% reported and 5% organic, the healthcare-systems-and-technologies segment grew 4% on both bases, and Advanced Surgery grew 12% reported. Five days after the earnings report, Baxter announced a $500 million cash tender offer for senior notes maturing in 2032, 2043, 2046 and 2051 - a step further into a deleveraging program that has already taken total debt from $14.1 billion at year-end 2024 to $9.7 billion. The market capitalization sits at roughly $13.8 billion against $9.7 billion of debt and $2.15 billion of cash, and the stock is up 56% from a 52-week low of $15.73 set in late 2025, but is still 11% off the 52-week high of $30.00. The open question is whether the next four quarters print the operating leverage that the multiple - roughly 12.7x forward adjusted earnings - is paying for, or whether the medical-products-and-therapies margin compression is the first signal of a more competitive product cycle.